SCHEMBL26424674

SCHEMBL26424674

CC(C)(C)c1c(F)cc(OCc2ccccc2)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.48
▸ CYP1A1 P04798 1/20 0.48
▸ CYP19A1 P11511 1/20 0.48
▸ MAOB P27338 6/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAOA P21397 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26424677 0.91 MRGPRX4 (0.44) CYP1A2CYP1A1CYP19A1MAOBMEN1
SCHEMBL14293620 0.81 MAPT (0.56) CYP1A2MAOBMEN1KMT2AALOX5
SCHEMBL17481249 0.81 ALOX5 (0.51) CYP1A2MAOBALOX5LMNAPTGS1
SCHEMBL24448850 0.78 ALOX5 (0.51) CYP1A2MAOBALOX5LMNAPTGS1
SCHEMBL16822503 0.77 APP (0.52) CYP1A2MAOBMEN1KMT2AALOX5
SCHEMBL16822606 0.77 MAOB (0.56) CYP1A2MAOBMEN1KMT2AALOX5
SCHEMBL1337716 0.77 MAOB (0.56) CYP1A2MAOBMEN1KMT2AALOX5
SCHEMBL20098899 0.77 MAOB (0.56) CYP1A2CYP1A1CYP19A1MAOBMEN1
SCHEMBL30332160 0.77 CTSV (0.42) CYP1A2MAOBMEN1KMT2AALOX5
SCHEMBL14268012 0.77 ALOX5 (0.50) CYP1A2MAOBMEN1KMT2AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130909-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-04-27 — — US disclosed
US-20230130909-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130909-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF WEE2, WEE1, HK1 CYP1A2 1808/4885CYP1A1 1405/4885CYP19A1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback